Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CASI Pharmaceuticals's change in inventory for the quarter that ended in Dec. 2025 was €0.00 Mil. It means CASI Pharmaceuticals's inventory
stayed the same
from Sep. 2025 to Dec. 2025 .
CASI Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2025 was €2.14 Mil. It means CASI Pharmaceuticals's inventory
declined by €2.14 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
CASI Pharmaceuticals's Days Inventory for the quarter that ended in Dec. 2025 was 54.34.
Inventory Turnover measures how fast the company turns over its inventory within a year.
CASI Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2025 was 1.68.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
CASI Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.29.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
CASI Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CASI Pharmaceuticals Change In Inventory Related Terms
CASI Pharmaceuticals Change In Inventory Historical Data
* Premium members only.
The historical data trend for CASI Pharmaceuticals's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CASI Pharmaceuticals Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of €0.00 Mil mean?
CASI Pharmaceuticals (FRA:ENM) has a Change In Inventory of €0.00 Mil as of Dec. 2025. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for CASI Pharmaceuticals and its competitors.
Is CASI Pharmaceuticals' Change In Inventory too high?
CASI Pharmaceuticals' current Change In Inventory is €0.00 Mil. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' Change In Inventory compare to DCOY and PKTX?
CASI Pharmaceuticals' Change In Inventory of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for CASI Pharmaceuticals and its competitors. CASI Pharmaceuticals's current Change In Inventory is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
CASI Pharmaceuticals (FRA:ENM) has a current Change In Inventory of €0.00 Mil. The stock's GF Value™ is €13.27, compared to a current price of €1.54 — trading 88.4% below its estimated fair value. The current Change In Inventory is €0.00 Mil. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For CASI Pharmaceuticals (FRA:ENM), the current Change In Inventory is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CASI Pharmaceuticals (FRA:ENM) Overvalued in 2026?
Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued.
The current stock price of €1.54 is trading 88.4% below its estimated GF Value™ of €13.27.
Key valuation signals for FRA:ENM:
Change In Inventory: €0.00 Mil
GF Value™: €13.27 vs. price of €1.54 (88.4% below fair value)
No single metric tells the full story. See the FRA:ENM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score
Get the complete analysis for FRA:ENM
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ENM has been successfully added to your 
